Received Jul 15, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
HCP called and reported that a patient received a first dose of GARDASIL 9 on 09MAY2025 at age 45 years old, and the patient is now due for her second dose of GARDASIL 9 and is currently 46 years old. Second dose has not yet been administered, but pr; No additional AE; This spontaneous report was received from a nurse and refers to a currently 46-year-old female patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 09-May-2025 (at age 45 years old), the patient received a first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), administered for prophylaxis (strength, dose, route, anatomical site, lot # and expiration date were not reported). The patient was now due for her second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9) and was currently 46 years old. Second dose has not yet been administered (Inappropriate schedule of product administration). Limited patient demographics provided. No additional information was known by reporter. No additional AE/PQC (No adverse event). Lot# is being requested and will be submitted if received.